Wednesday September 27, 8:12 am Eastern Time
Press Release
Telik Awarded SBIR Grant From NIH for New
Applications of Proprietary Chemogenomic Drug
Discovery Technology
SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--Sept. 27, 2000-- Telik, Inc. (Nasdaq:TELK - news) today
announced that it has received a Small Business Innovation Research (SBIR) grant from the National Institutes of Health
(NIH). This grant will support the application of Telik's proprietary chemogenomics drug discovery technology, TRAP, for the
identification of new small molecule modulators of caspase 3, an enzyme that plays a critical role in diseases of the central
nervous system as well as many types of cancer.
``We believe that the speed and efficiency of TRAP is well suited for the rapid identification of new drug candidates in the post
genomic era. We plan to use TRAP to identify new drug candidates that can modulate caspase 3 activity in order to exert a
therapeutic effect in various diseases,'' said Dr. Michael Kozlowski, Telik's vice president of biology.
``Telik will continue to use our technology platform to add to our own product candidate pipeline as well as those of our
corporate partners,'' said Dr. Michael Wick, chairman and chief executive officer. ``We are pleased that the value of applying
TRAP to accelerate the small molecule drug discovery process is being recognized by the NIH.''
Telik, Inc. of South San Francisco, California, is a biopharmaceutical company working to discover, develop, and
commercialize small molecule drugs to treat serious diseases for which there is significant demand for new therapies. The
company's most advanced development programs are for the treatment of cancer and diabetes. Telik's product candidates
were all discovered using its proprietary technology known as TRAP, which enables the rapid and efficient discovery of small
molecule drug candidates. Additional information can be found at www.telik.com.
You should not rely on forward-looking statements contained in this press release including, but not limited to, statements
regarding our ability to identify small molecule modulators of caspase 3 using TRAP, and the potential of such modulators to
lead to the development of safer or more effective therapies. Telik can give no assurance with regard to these statements.
TRAP may not identify small molecule modulators of caspase 3 that will be beneficial in humans. More detailed information
regarding risk factors is set forth under the caption ``Risk Factors'' in our prospectus filed with the Securities and Exchange
Commission on August 11, 2000.
Contact:
Telik, Inc.
Carol DeGuzman, 650/238-3370
cdeguzman@telik.com |
